Valvular heart disease associated with fenfluramine-phentermine
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million. METHODS: We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease. The women presented with cardiovascular symptoms or a heart murmur. As increasing numbers of these patients with similar clinical features were identified, there appeared to be an association between these features and fenfluramine-phentermine therapy. RESULTS: Twenty-four women (mean [+/-SD] age, 44+/-8 years) were evaluated 12.3+/-7.1 months after the initiation of fenfluramine-phentermine therapy. Echocardiography demonstrated unusual valvular morphology and regurgitation in all patients. Both right-sided and left-sided heart valves were involved. Eight women also had newly documented pulmonary hypertension. To date, cardiac surgical intervention has been required in five patients. The heart valves had a glistening white appearance. Histopathological findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture. The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease. CONCLUSIONS: These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular heart disease. Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [70]
Citations
Cites
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993) · Circulation · doi:10.1161/01.cir.87.4.1188 · Cited by 614
Robiolio, P. A., Rigolin, V. H., Wilson, J. S., Harrison, J. K., Sanders, L. L., Bashore, T. M., & Feldman, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.4.790 · Cited by 406
Doppler Echocardiography: Theory, Instrumentation, Technique, and Application
NISHIMURA, R. A., MILLER, F. A., CALLAHAN, M. J., BENASSI, R. C., SEWARD, J. B., & TAJIK, A. J. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60540-0 · Cited by 263
Primary pulmonary hypertension and fenfluramine use.
Brenot, F., Herve, P., Petitpretz, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 251
Weir, E. K., Reeve, H. L., Huang, J. M. C., Michelakis, E., Nelson, D. P., Hampl, V., & Archer, S. L. (1996) · Circulation · doi:10.1161/01.cir.94.9.2216 · Cited by 218
Klein, A. L., Burstow, D. J., Tajik, A. J., Zachariah, P. K., Taliercio, C. P., Taylor, C. L., Bailey, K. R., & Seward, J. B. (1990) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(14)80299-x · Cited by 213
Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-50 · Cited by 156
Self-citationHormonal responses to fenfluramine in depressed and control subjects
Mitchell, P. B., & Smythe, G. A. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90008-v · Cited by 99
Irreversible pulmonary hypertension after treatment with fenfluramine.
McMurray, J. J. V., Bloomfield, P. M., & Miller, H. (1986) · BMJ · doi:10.1136/bmj.292.6515.239-a · Cited by 50
Research works printed but not linked: 4
- Heuer L, 1978, Chir Prax, 23, 497
- Tajik AJ, 1978, Mayo Clin Proc, 53, 271
- Thorson AH, 1958, Acta Med Scand Suppl, 334, 99
- Morita T, 1983, Am Rev Respir Dis, 127, 747
Cited by
Items 801–900 of 1,001
Boot, B. P., Partridge, B., & Hall, W. (2011) · Neurocase · doi:10.1080/13554794.2011.588174 · Cited by 18
Additional Insights Into Pergolide-Associated Valvular Heart Disease
Lanier, W. L. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.6.684 · Cited by 18
Schiller, N. B. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00315-0 · Cited by 18
Boudes, A., Lavoûte, C., Aviérinos, J.-F., Dolley, Y. L., Villacampa, C., Salem, A., Loundou, A., Michel, N., Renard, S., & Habib, G. (2011) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ejechocard/jer116 · Cited by 17
Severe hepatic injury and adulterated Chinese medicines
Lai, V., Smith, A. J., Thorburn, D., & Raman, V. (2006) · BMJ · doi:10.1136/bmj.332.7536.304-b · Cited by 17
Analysis of the Drugs Withdrawn from the US Market from 1976 to 2010 for Safety Reasons
Rochelle, P. L., Lexchin, J., & Simonyan, D. (2016) · Pharmaceutical Medicine · doi:10.1007/s40290-016-0159-1 · Cited by 17
Capristo, E., Maione, A., Lucisano, G., Russo, M. F., Mingrone, G., & Nicolucci, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.05.023 · Cited by 18
Review: Genetics of the cardiometabolic syndrome: new insights and therapeutic implications
Sookoian, S. C., & Pirola, C. J. (2007) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944707082702 · Cited by 23
Vascular actions of 3,4-methylenedioxymethamphetamine in α2A/D-adrenoceptor knockout mice
Vandeputte, C., & Docherty, J. R. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02661-4 · Cited by 17
Perez, J. N., Diaz, N. S., Tandon, I., Plate, R., Martindale, C., & Balachandran, K. (2017) · Cardiovascular Engineering and Technology · doi:10.1007/s13239-017-0298-x · Cited by 19
Tricuspid valve disease: Tricuspid valve complex perspective
Raman, S. V., SPARKS, E., Boudoulas, H., & Wooley, C. F. (2002) · Current Problems in Cardiology · doi:10.1016/s0146-2806(02)70012-1 · Cited by 17
Watts, G. F., Herrmann, S., & Riches, F. M. (2000) · QJM · doi:10.1093/qjmed/93.3.153 · Cited by 17
In-vitro contraction of the equine aortic valve.
Bowen, M., Marr, C. M., Chester, A. H., Wheeler-Jones, C. P. D., & Elliott, J. (2004) · PubMed · Cited by 17
Outcomes of Pharmacological and Surgical Treatment for Obesity
Cerulli, J., & Malone, M. (1998) · PharmacoEconomics · doi:10.2165/00019053-199814030-00004 · Cited by 17
Drug Therapy for Obesity in the Elderly
Dvorak, R. V., Starling, R. D., Calles-Escandón, J., Sims, E. A. H., & Poehlman, É. T. (1997) · Drugs & Aging · doi:10.2165/00002512-199711050-00002 · Cited by 17
Biologic Approaches to Treatment-Refractory Obsessive-Compulsive Disorder
Goodman, W. K., Ward, H. E., & Murphy, T. K. (1998) · Psychiatric Annals · doi:10.3928/0048-5713-19981101-09 · Cited by 20
Bray, G. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.10 · Cited by 18
A perspective on the regulation of the evaluation of new antithrombotic drugs
Califf, R. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00661-4 · Cited by 17
Mikhailidis, D. P. (2000) · Platelets · doi:10.1080/095371000403099 · Cited by 17
Strother, J., Fedullo, P. F., Yi, E. S., & Masliah, E. (1999) · Archives of Pathology & Laboratory Medicine · doi:10.5858/1999-123-0539-cvlaai · Cited by 17
A Historical Overview Upon the Use of Amphetamine Derivatives in the Treatment of Obesity
Stăcescu, Ș., Hancu, G., Podar, D., Todea, Ș., & Tero-Vescan, A. (2020) · Journal of Pharmaceutical Care · doi:10.18502/jpc.v7i3.2355 · Cited by 19
Anti-obesity weight loss medications: Short-term and long-term use
Jeong, D., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120825 · Cited by 21
Dini, G., Cara, G. D., Ferrara, P., Striano, P., & Verrottı, A. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s417676 · Cited by 16
Steinman, J. R., & DeBoer, M. D. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-410473-0.00008-8 · Cited by 16
Tribouilloy, C. M., Maréchaux, S., Jobic, Y., Jeu, A., Éderhy, S., Donal, E., Réant, P., Arnalsteen, E., Boulanger, J., Garban, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht266 · Cited by 16
Valvular Heart Disease and Heart Failure: Dental Management Considerations
Warburton, G., & Caccamese, J. F. (2006) · Dental Clinics of North America · doi:10.1016/j.cden.2006.06.010 · Cited by 19
Obesity Drug Update: The Lost Decade?
Yao, F., & MacKenzie, R. G. (2010) · Pharmaceuticals · doi:10.3390/ph3123494 · Cited by 18
Bazan, I. S., & Fares, W. H. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.02.049 · Cited by 17
Joll, J. E., Clark, C. R., Peters, C. S., Raddatz, M. A., Bersi, M. R., & Merryman, W. D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238407 · Cited by 16
“Endocrine diseases leading to overexpression of serotonin, such as carcinoid tumors, have been linked with multiple valvulopathies, and serotonin receptor agonists such as Fenfluramine (an anti-obesity drug marketed in the 1990s) have been clearly shown to exacerbate valve disease [10, 11].”
BackgroundValvular Heart Disease: A Century of Progress
Sharma, S., Mehra, A., & Rahimtoola, S. H. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.027 · Cited by 17
Greffe, G., Chalabreysse, L., Mouly-Bertin, C., Lantelme, P., Thivolet, F., Aulagner, G., & Obadia, J. (2007) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2006.11.031 · Cited by 16
Halpern, A., Leite, C. C., Herszkowicz, N., Barbato, A. J. G., & da Costa, A. P. H. (2002) · Revista do Hospital das Clínicas · doi:10.1590/s0041-87812002000300003 · Cited by 16
Recent Advances in Anti-Obesity Agents
Kim, M. K., & Kim, C. S. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.6.501 · Cited by 16
The Acute Effects of Dexfenfluramine on Human and Porcine Pulmonary Vascular Tone and Resistance
HIGENBOTTAM, T. W., Marriott, H. M., Cremona, G., Laude, E. A., & Bee, D. (1999) · CHEST Journal · doi:10.1378/chest.116.4.921 · Cited by 16
To Treat or Not to Treat: That is the Question
Bray, G. A. (1997) · Obesity Research · doi:10.1002/j.1550-8528.1997.tb00586.x · Cited by 16
Roldan, C. A., Gill, E. A., & Shively, B. K. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01008-0 · Cited by 16
Caffeine: a potential mechanism for anti-obesity
Wang, M., Guo, W. Y., & Chen, J. (2024) · Purinergic Signalling · doi:10.1007/s11302-024-10022-1 · Cited by 15
Mitral bioprosthesis hypertrophic scaring and native aortic valve fibrosis during benfluorex therapy
Ayme‐Dietrich, E., Lawson, R., Gasser, B., Dallemand, R., Bischoff, N., & Monassier, L. (2012) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2012.01027.x · Cited by 15
Pharmacotherapy for Obesity: Past, Present and Future
Hsu, Y.-W., Chu, D.-C., Ku, P., Liou, T., & Chou, P. (2010) · Journal of Experimental & Clinical Medicine · doi:10.1016/s1878-3317(10)60019-8 · Cited by 21
Bohula, E. A., Scirica, B. M., Fanola, C. L., Inzucchi, S. E., KEECH, A. C., McGuire, D. K., Smith, S. R., Abrahamsen, T. E., Francis, B. H., Miao, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.03.012 · Cited by 15
Cardiovascular and temperature adverse actions of stimulants
Docherty, J. R., & Alsufyani, H. A. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15465 · Cited by 16
Maréchaux, S., Jeu, A., Jobic, Y., Éderhy, S., Donal, E., Réant, P., Abouth, S., Arnasteen, E., Boulanger, J., Ennezat, P., et al. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.04.006 · Cited by 15
Binge Eating Disorder: Diagnosis and Treatment Options
Brewerton, T. D. (1999) · CNS Drugs · doi:10.2165/00023210-199911050-00003 · Cited by 15
Hopkins, W. E. (2012) · Cardiology Clinics · doi:10.1016/j.ccl.2012.03.006 · Cited by 17
Pavone, L. M., & Norris, R. A. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9606-8 · Cited by 17
Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents
Walter, C. P., Bleske, B. E., & Dorsch, M. P. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12177 · Cited by 18
Off-label use of drugs: An evil or a necessity?
Divatia, J., & Gota, V. (2015) · Indian Journal of Anaesthesia · doi:10.4103/0019-5049.171555 · Cited by 15
New Antiobesity Agents: Lorcaserin (Belviq) and Phentermine/Topiramate ER (Qsymia)
Shyh, G. I., & Cheng-Lai, A. (2013) · Cardiology in Review · doi:10.1097/crd.0000000000000001 · Cited by 18
Vaideeswar, P., & BUTANY, J. W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-420219-1.00012-4 · Cited by 15
Cardiovascular Safety and Superiority of Anti-Obesity Medications
Alobaida, M., Alrumayh, A., Oguntade, A. S., Al-Amodi, F., & Bwalya, M. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s311359 · Cited by 15
Role of dopamine agonists in Parkinson’s disease: an update
Bonuccelli, U., & Pavese, N. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.10.1391 · Cited by 18
Effects of prenatal co-administration of phentermine and dexfenfluramine in rats
Bratter, J., Gessner, I. H., & Rowland, N. E. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00100-4 · Cited by 15
Ischemic Colitis after Weight-Loss Medication
Comay, D., Ramsay, J., & Irvine, E. J. (2003) · Canadian Journal of Gastroenterology · doi:10.1155/2003/167127 · Cited by 16
“However, subsequent reports linking fenfluramine and dexfenfluramine to the development of pulmonary hypertension and cardiac valvular abnormalities led to a dramatic decline in their use, as well as that of phentermine (7-10).”
BackgroundCarcinoid tumors, carcinoid syndrome and related disorders
Öberg, K. (2007) · Cited by 15
Weight-Loss Pharmacotherapy: A Brief Review
Huizinga, M. M. (2007) · Clinical Diabetes · doi:10.2337/diaclin.25.4.135 · Cited by 16
Impact of Obesity in Patients With Congestive Heart Failure
Kunju, S. U., Badarudeen, S., & Schwar, E. R. (2009) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0480 · Cited by 15
Anxiolytics, Sedatives, and Miscellaneous Drugs
WERRY, J. S., & Aman, M. G. (1999) · Springer eBooks · doi:10.1007/978-1-4899-0086-9_15 · Cited by 16
The "Phen-Pro" Diet Drug Combination Is Not Associated With Valvular Heart Disease
Griffen, L., & Anchors, M. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.11.1278 · Cited by 15
Use of Stiripentol in Dravet Syndrome: A Guide for Clinicians
Wheless, J. W., & Weatherspoon, S. E. (2024) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2024.10.015 · Cited by 16
Effects of lorcaserin on pre‐existing valvulopathy: A pooled analysis of phase 3 trials
Weissman, N. J., Smith, S. R., Fain, R., Hall, N., & Shanahan, W. R. (2016) · Obesity · doi:10.1002/oby.21695 · Cited by 14
Serotonin and Cardiovascular Diseases
Monassier, L., & Maroteaux, L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-800050-2.00012-7 · Cited by 17
Dahlberg, S., Chang, E. T., Weiss, S. R., Dopart, P. J., Gould, E. M., & Ritchey, M. E. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s381652 · Cited by 17
Boisvert, J. P., Boschuetz, T. J., Resch, J. M., Mueller, C. R., & Choi, S. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.05.011 · Cited by 16
Safety First: Precautions for the Massive Weight Loss Patient
Davison, S. P., & Clemens, M. W. (2007) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2007.08.002 · Cited by 16
Valvular and Mural Endocardiosis in Aging Zebrafish ( Danio rerio )
Cooper, T. K., & Spitsbergen, J. M. (2015) · Veterinary Pathology · doi:10.1177/0300985815594853 · Cited by 14
“Activation of serotonergic 5-hydroxytryptamine 2B receptors in carcinoid syndrome can result in myxomatous valve disease in humans.(6,8,19) Therefore, we specifically looked for any association between valvular endocardiosis and the occurrence of small cell tumors (carcinoids) of the intestine.”
BackgroundAntiepileptic Drugs in Clinical Development: Differentiate or Die?
Zaccara, G., & Schmidt, D. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170809100524 · Cited by 14
Reducing the prevalence of obesity in Canada: a call to action
Shentow-Bewsh, R., & Zuberi, D. M. (2018) · Social Work in Public Health · doi:10.1080/19371918.2018.1482252 · Cited by 15
“For example, one popular weight loss pill used for decades in the United States, fenfluramine-phentermine, was taken off the market by the Food and Drug Adinistration (FDA) in 1997 after it was found to be associated with heart complications (Cogan, 1999; Connolly et al., 1997).”
BackgroundStrom, B. L. (2012) · Pharmacoepidemiology · doi:10.1002/9781119959946.ch1 · Cited by 14
Therapeutic Considerations in the Treatment of Obesity Hypertension
Wofford, M. R., Davis, M. M., Harkins, K. G., King, D. S., Wyatt, S. B., & Jones, D. W. (2002) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.00502.x · Cited by 15
Obesity Epidemic in the United States
Hunsaker, D. M., & Hunsaker, J. C. (2005) · Humana Press eBooks · doi:10.1385/1-59259-872-2:061 · Cited by 14
Nonsurgical and Surgical Treatment of Obesity
Neligan, P. J., & Williams, N. N. (2005) · Anesthesiology Clinics of North America · doi:10.1016/j.atc.2005.03.008 · Cited by 16
“In 1997, Connolly et al [14] reported 24 cases of valvular heart disease in women with no previous cardiac history who were taking phen-fen.”
BackgroundMethodInfluentialJohnson, G. J., Leis, L. A., Dunlop, P. C., & Weir, Ε. K. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00474.x · Cited by 16
Drug Therapy for Obesity--A Therapeutic Option?
Aronne, L. J. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.1.5392-2 · Cited by 14
Anorectic drugs and vascular disease:
Michelakis, E. D. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(02)00126-x · Cited by 14
The Longitudinal Effects of Fenfluramine-Phentermine Use
Fleming, R. M., & Boyd, L. B. (2007) · Angiology · doi:10.1177/0003319707302496 · Cited by 14
Medical management of obstructive sleep apnea
Henderson, J. H., & Strollo, P. J. (1999) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.1999.0410377 · Cited by 20
Sirois, D. A., & Fatahzadeh, M. (2001) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1067/moe.2001.111550 · Cited by 14
Sliding Scale Insulin Use and Rates of Hyperglycemia
Gaster, B., & Hirsch, I. B. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.1.95 · Cited by 14
Use of sibutramine to treat obesity
Ryan, D. H. (2003) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00005-8 · Cited by 14
“Although a small (n = 121) set of patients formed this study population, the regimen was used widely in clinical practices for 5 years after the trial was published until 1997, when fenfluramine and dexfenfluramine were associated with the previously unsuspected complication of cardiac valvulopathy [15].”
ResultAnother Chromosomal Locus for Mitral Valve Prolapse: Close but No Cigar
Roberts, R. (2005) · Circulation · doi:10.1161/circulationaha.105.569517 · Cited by 14
Childhood obesity: The measurable and the meaningful
Charney, E. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70427-5 · Cited by 14
Is Obesity Worth Treating in the Elderly?
Anta, R. M. O., & s, P. A. E. (1998) · Drugs & Aging · doi:10.2165/00002512-199812020-00002 · Cited by 14
“[26]”
Disorders of the Endocrine System and of Metabolism
Schifter, M., McLean, M. P., & Sukumar, S. (2021) · Wiley eBooks · doi:10.1002/9781119597797.ch22 · Cited by 18
State‐of‐the‐art management of Dravet syndrome
Vasquez, A., & Wirrell, E. C. (2025) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.16475 · Cited by 14
Lee, M. J. (2014) · International Journal of Gastroenterology Disorders & Therapy · doi:10.15344/2393-8498/2014/108 · Cited by 13
Delineating a serotonin 1B receptor circuit for appetite suppression in mice
Li, L., Wyler, S. C., Mercado, L. L., Xu, B., Oh, Y., SWATI, S., Chen, X., Wan, R., Arnold, A. G., Jia, L., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20212307 · Cited by 13
“For example, d-fenfluramine was banned after reports of valvular heart disease and pulmonary hypertension in users (Connolly et al., 1997).”
BackgroundKoutroumanidou, E., & Pagonopoulou, O. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2475 · Cited by 17
Carmody, J. S., Ahmad, N. N., Machineni, S., Lajoie, S., & Kaplan, L. M. (2015) · Endocrinology · doi:10.1210/en.2015-1226 · Cited by 14
Fixed-dose combination of phentermine–topiramate for the treatment of obesity
Halpern, B., Faria, A. M., & Halpern, A. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.13 · Cited by 13
Fielden, M. R., Hassani, M., Uppal, H., Day-Lollini, P. A., Button, D. C., Martin, R. S., Garrido, R., Liu, X., & Kolaja, K. L. (2009) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2009.08.009 · Cited by 13
Kaddoumi, A., Kubota, A., Nakashima, M. N., Takahashi, M., & Nakashima, K. (2001) · Biomedical Chromatography · doi:10.1002/bmc.85 · Cited by 13
Valvular Heart Disease in Hyperprolactinemic Patients Treated With Low Doses of Cabergoline
Cordoba-Soriano, J. G., Lamas, C., Hidalgo-Olivares, V. M., Martínez, A. T., Barambio-Ruíz, M., & Salas-Nieto, J. (2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2012.10.016 · Cited by 13
Grottick, A. J., Whelan, K. T., Sanabria, E. K., Behan, D. P., Morgan, M. E., & Sage, C. R. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3829-2 · Cited by 14
Comparative Efficiency and Safety of Pharmacological Approaches to the Management of Obesity
Hainer, V. (2011) · Diabetes Care · doi:10.2337/dc11-s255 · Cited by 18
Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity
Saunders, K. H., Kumar, R. B., Igel, L. I., & Aronne, L. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0589-y · Cited by 13
Evaluating anecdotes and case reports.
Isaacs, L. L. (2007) · PubMed · Cited by 13
Pulmonary Arterial Hypertension Secondary to Drugs and Toxins
Ramírez, R. L., Pienkos, S. M., Pérez, V. D. J., & Zamanian, R. T. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.11.008 · Cited by 14
Ennezat, P., Cosgrove, S., Bouvaist, H., Maréchaux, S., Guerbaaï, R.-A., Jemtel, T. H. L., Andréjak, M., & Vital-Durand, D. (2017) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2017.01.011 · Cited by 17
Cardiovascular and Skeletal Muscle Systems
VanVleet, J. F., Ferrans, V. J., & Herman, E. (2002) · Elsevier eBooks · doi:10.1016/b978-012330215-1/50036-3 · Cited by 13
Simonds, S. E., Pryor, J. T., Koegler, F. H., Buch-Rasmussen, A. S., Kelly, L. E., Grove, K. L., & Cowley, M. A. (2019) · Diabetes · doi:10.2337/db18-1149 · Cited by 13
Metadata
- Authors
- Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-08-28
- Volume
- 337
- Issue
- 9
- Pages
- 581-588
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2134362869
- Cited by
- 1,632
- References
- 14
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 26 · 2023: 43 · 2022: 32 · 2021: 40 · 2020: 35 · 2019: 39 · 2018: 42 · 2017: 55 · 2016: 54 · 2015: 58 · 2014: 51 · 2013: 55 · 2012: 59
- FWCI
- 72.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Issues in Pregnancy
- Keywords
- valvular heart disease, pulmonary hypertension, anorectic agents, women, adverse drug reactions
- MeSH terms
- Adult, Aortic Valve Insufficiency, Appetite Depressants, Drug Combinations, Female, Fenfluramine, Heart Valve Diseases, Humans, Hypertension, Pulmonary, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Phentermine, Tricuspid Valve Insufficiency, Ultrasonography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.